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Abstract
 
Ionizing radiation and cytotoxic drugs used in the treatment of cancer induce apoptosis in
many cell types, including tumor cells. It has been reported that tumor cells treated with anti-
cancer drugs increase surface expression of Fas ligand (FasL) and are killed by autocrine or para-
crine apoptosis signaling through Fas (Friesen, C., I. Herr, P.H. Krammer, and K.-M. Debatin.
1996. 
 
Nat. Med.
 
 2:574–577). We show that lymphocytes that cannot be killed by FasL, such as
those from Fas-deficient 
 
lpr
 
 mice or transgenic mice expressing a dominant negative mutant of
Fas-associated death domain protein (FADD/MORT1), are as sensitive as normal lymphocytes
to killing by gamma radiation
 
 
 
or the cytotoxic drugs cis-platin, doxorubicin, and etoposide. In
contrast, p53 deficiency or constitutive expression of Bcl-2 markedly increased the resistance of
lymphocytes to gamma radiation or anticancer drugs but had no effect on killing by FasL. Consis-
tent with these observations, 
 
lpr
 
 and wild-type T cells both had a reduced capacity for mitogen-
induced proliferation after drug treatment, whereas 
 
bcl-2
 
 transgenic or p53-deficient T cells
retained significant clonogenic potential. These results demonstrate that apoptosis induced by
ionizing radiation or anticancer drugs requires p53 and is regulated by the Bcl-2 protein family
but does not require signals transduced by Fas and FADD/MORT1.
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Introduction
 
Fas (also known as CD95 or APO-1) belongs to a subset of
the TNFR family, whose members have a cytoplasmic ‘death
domain.’ When Fas is engaged by multimeric Fas ligand (L),
its death domain binds to the death domain in the cytoplas-
mic adaptor protein FADD/MORT1 (Fas-associated death
domain protein). A further homotypic interaction occurs be-
tween the ‘death effector domain’ in FADD/MORT1 and a
death effector domain in procaspase-8. The close proximity
of caspase-8 zymogens facilitates their autocatalytic activa-
tion, and this appears to initiate the proteolytic cascade that
leads to apoptosis (1). It has been proposed that Fas signaling
plays a critical role in drug-induced apoptosis, stemming
from the observation that neutralization of FasL prevented
doxorubicin-induced apoptosis in T cell leukemia lines (2).
Subsequent reports have differed as to whether impaired Fas
signaling in tumor cell lines blocks (3–5) or has no effect (6–
14) on drug-induced apoptosis. As mutations affecting the
cell death machinery can contribute to tumor formation
(15–18), these discrepancies may have arisen because the
transformed cell lines studied harbor unknown mutations in
genes that regulate cell death. To avoid such complications,
we sought evidence of a role for Fas and FADD/MORT1 in
gamma radiation– and drug-induced apoptosis using non-
transformed cells. We used lymphocyte populations from ge-
netically modified mice to determine if nontransformed cells
that are resistant to FasL-induced apoptosis are also refractory
to cytotoxic anticancer treatments.
 
Materials and Methods
 
Mice.
 
All experiments with mice were approved by the
Royal Melbourne Hospital Research Foundation Animal Ethics
Committee. 
 
lck
 
pr
 
-FADD-DN (dominant negative) strain 64 trans-
genic mice (19), E
 
m
 
-
 
bcl
 
-2-36 and E
 
m
 
-
 
bcl
 
-2-25 transgenic mice (20),
Fas-deficient mutant 
 
lpr
 
 mice (21), and 
 
p53
 
2
 
/
 
2
 
 mice (22) have been
described previously. All animals had a C57BL/6J genetic back-
ground. 
 
bcl
 
-2 transgenic T cells were isolated from E
 
m
 
-
 
bcl
 
-2-25
mice, whereas 
 
bcl
 
-2 transgenic B cells were isolated from E
 
m
 
-
 
bcl
 
-
2-36 mice. Spleen B cells and lymph node T cells were purified by
negative cell sorting in a FACSII™ or FACStar
 
PLUS™
 
 sorter (Becton
Dickinson). FITC-negative,
 
 
 
propidium iodide (PI)-negative cells
were selected after surface staining with a cocktail of FITC-con-
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jugated mAbs. MI/70 anti–Mac-1, 8C5 anti–Gr-1, Ter119 anti-
erythroid cell surface marker, RA3-6B2 anti-B220, 5.1 anti-IgM,
and 11-26C anti-IgD antibodies were used to isolate T cells.
MI/70 anti–Mac-1, 8C5 anti–Gr-1, Ter119 antierythroid cell
surface marker, H129.19.6.8 anti-CD4, YTS 169 anti-CD8, and
T24.31.2 anti–Thy-1 antibodies were used to isolate B cells.
 
Cell Survival Experiments.
 
Lymphocytes were cultured in the
high-glucose version of DME supplemented with 13 
 
m
 
M folic
acid, 250 
 
m
 
M 
 
l
 
-asparagine, 50 
 
m
 
M 2-ME, and 10% FCS (Bio-
sciences; starting concentration 10
 
5
 
 cells/ml). B cells were stimu-
lated with 20 
 
m
 
g/ml LPS, 20 
 
m
 
g/ml F(ab
 
9
 
)
 
2
 
 
 
goat anti–mouse IgM
(Jackson ImmunoResearch), 100 U/ml IL-2, and 100 U/ml IL-4
plus 100 U/ml IL-5. T cells were stimulated with immobilized
KT3 rat anti–mouse CD3 and 37N51 hamster anti–mouse CD28
antibodies plus 100 U/ml IL-2. Tissue culture plates were coated
in PBS that contained 10 
 
m
 
g/ml of each antibody. Resting and
activated cells were treated with gamma radiation (2.5–10 Gy
from a 
 
60
 
Co source), 5–500 ng/ml doxorubicin (David Bull Labs.),
0.1–10 
 
m
 
g/ml etoposide, and 0.1–10 
 
m
 
g/ml cis-platin (Della
West Pty Ltd.) or were cultured on Neuro-2A.FasL or Neuro-
2A.neo cell monolayers (23). Activated cells were maintained in
cytokines during treatment to minimize death due to growth fac-
tor withdrawal. Cell viability was determined by flow cytometric
analysis of PI-stained cells in a FACScan™ (Becton Dickinson).
To correct for doxorubicin fluorescence at higher doses, living
and dead cells were also discriminated on the basis of their for-
ward and side light-scattering properties.
To determine clonogenic survival, purified T cells were incu-
bated for 8 h at 37
 
8
 
C in medium that contained 0, 0.1, 1, or 5
 
m
 
g/ml cis-platin or etoposide. Cells were then washed free of
drug and plated at limiting dilution with 2 ng/ml PMA and 0.1
 
m
 
g/ml ionomycin plus 100 U/ml IL-2 in flat-bottomed 96-well
plates. Three dilutions (1, 5, 10, 50, or 100 cells/well) were pre-
pared for each treatment, and 96 wells were prepared for each di-
lution. Wells were scored microscopically as positive or negative
for T cell growth after 7-d incubation at 37
 
8
 
C. The surviving
fraction (
 
S
 
) after each treatment was calculated according to the
equation: 
where 
 
x
 
 is the fraction of wells negative for cell growth and 
 
y
 
 is
the number of cells initially plated per well for treated (i) and un-
treated (u) cells (24). In other words, comparisons were made of
the slopes of graphs plotting ln (fraction of wells negative for
growth) versus the number of cells plated per well.
 
Results and Discussion
 
We have previously shown that T cells from Fas-defi-
cient 
 
lpr
 
 mice (21) and FADD-DN transgenic mice that ex-
press a dominant interfering mutant of FADD/MORT1 (19)
are highly resistant to apoptosis induced by cross-linked solu-
ble human FasL (19). Resistance was also observed when we
cultured the cells with Neuro-2A neuroblastoma cells stably
transfected with a mouse FasL expression construct (Fig. 1,
A and B). These Neuro-2A.FasL cells express membrane-
anchored FasL because they lack the matrix metalloprotein-
ase responsible for FasL cleavage from the cell surface (23).
In contrast, wild-type thymocytes and mature T cells un-
derwent extensive apoptosis when cultured with Neuro-
2A.FasL cells (Fig. 1, A and B). FasL triggered this apopto-
S ln xi () yi ¤ [] yu ln xu () ¤ [] , × =
 
sis, because it was not observed in lymphocytes cultured
with Neuro-2A.neo cells transfected with vector DNA
(data not shown). Similarly, wild-type T cells activated in
culture
 
 
 
for 3 d with cross-linking antibodies to CD3 and
CD28 or wild-type B cells activated with LPS plus anti-
IgM antibody for 3 d were sensitive to FasL killing, whereas
their 
 
lpr
 
 counterparts were resistant (Fig. 1, D and E). Wild-
type resting B cells were more resistant than activated B
cells to FasL killing (Fig. 1 C), presumably due to very low
surface expression of Fas (data not shown). The effect of
FADD-DN on the sensitivity of B cells to killing by FasL
could not be examined, because FADD-DN expression is
limited to T cells in our transgenic mice. The proliferation
defect of FADD-DN T cells prevented examination of ac-
tivated FADD-DN T cells (19). As the anti-apoptotic pro-
tein Bcl-2 and the tumor suppressor p53 are known modu-
lators of gamma radiation– and drug-induced apoptosis (22,
24–27), we included in our analysis lymphocytes from 
 
bcl
 
-2
transgenic mice (20) and 
 
p53
 
-deficient mice (22). Neither
p53 deficiency nor constitutive expression of Bcl-2 protected
lymphocytes from apoptosis induced by FasL (Fig. 1, A–E).
To test sensitivity to a range of anticancer treatments, lym-
phocytes were exposed in culture to ionizing radiation
(2.5–10  Gy) or the cytotoxic drugs cis-platin (0.1–10 
 
m
 
g/ml),
doxorubicin (50–500 ng/ml), and etoposide (0.1–10 
 
m
 
g/ml).
Cell survival was determined after 24 and 48 h. Apoptosis in
cultures of wild-type, 
 
lpr
 
, or FADD-DN transgenic lympho-
cytes occurred in a similar dose-dependent manner (Fig. 1),
and a comparison of the kinetics of cell killing revealed no
difference between the three genotypes (Fig. 2). In con-
trast, thymocytes and resting mature B and T cells from
 
p53
 
2
 
/
 
2
 
 or 
 
bcl
 
-2 transgenic mice were resistant to these apop-
totic stimuli. For example, 2 d after a 10-Gy dose of gamma
radiation or continuous culture in 1 
 
m
 
g/ml etoposide,
 
.
 
70% of all wild-type, 
 
lpr
 
, and FADD-DN transgenic thy-
mocytes were dead, whereas apoptosis in cultures of simi-
larly treated 
 
p53
 
2
 
/
 
2
 
 or 
 
bcl
 
-2 transgenic thymocytes did not
exceed 20% (Fig. 2 A). Interestingly, enforced Bcl-2 ex-
pression or p53 deficiency had relatively little impact on the
death of gamma-irradiated or drug-treated cycling cells
(Fig. 1, D–E, and Fig. 2, D–E).
Short-term survival assays may only reflect differences in
the rate of cell killing. For cancer treatment, the critical
determinant of success is whether or not cells retain the
capacity to proliferate in the long term. Therefore, we exam-
ined the capacity of drug-treated T cells for mitogen-induced
proliferation. Resting mature T cells from wild-type, 
 
lpr
 
,
 
bcl
 
-2 transgenic, and 
 
p53
 
2
 
/
 
2
 
 mice were cultured in varying
concentrations of etoposide or cis-platin (0, 0.1, 1, and 5
 
m
 
g/ml) for 8 h and then plated at limiting dilution in 96-
well microtiter plates containing PMA and ionomycin plus
recombinant IL-2. Plates were scored microscopically for T
cell proliferation 7 d later. The results of these experiments
are shown in Fig. 3. Clonogenic survival of wild-type cells
decreased as the dose of drug increased. There was on aver-
age a 260-fold drop in the frequency of clonogenic cells af-
ter culture in 5 
 
m
 
g/ml cis-platin (Fig. 3 A) and a 12-fold drop
after culture in 5 
 
m
 
g/ml etoposide (Fig. 3 B). 
 
lpr
 
 T cells 
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treated with cis-platin or etoposide exhibited a similar drop
in clonogenic survival (Fig. 3). In comparison, enforced
Bcl-2 expression or loss of p53 markedly enhanced clono-
genic survival after exposure to cis-platin and etoposide. Af-
ter treatment with 5 
 
m
 
g/ml cis-platin, clonogenic survival
of 
 
bcl
 
-2 transgenic and 
 
p53
 
2
 
/
 
2
 
 T cells was reduced 16- and
8-fold, respectively (Fig. 3 A), and after treatment with
5 
 
m
 
g/ml etoposide, cells of both genotypes showed only a
1.8-fold reduction in clonogenic survival (Fig. 3 B).
We conclude from our findings that signals transduced
by Fas and/or FADD/MORT1 are dispensable for ionizing
radiation– and cytotoxic drug–induced apoptosis in lympho-
Figure 1. Gamma radiation and cytotoxic drugs can kill lymphocytes that are resistant to FasL. Thymocytes (A), mature T cells (B and D), and mature
B cells (C and E) were isolated from wild-type, bcl-2 transgenic, FADD-DN transgenic, lpr, or p532/2 mice. Resting cells (A–C) or cells that had been
activated for 3 d with mitogens (D and E) were cultured with Neuro-2A.FasL cells, subjected to gamma irradiation (2.5–10 Gy), or cultured in the con-
tinuous presence of cytotoxic drugs (0.1–10 mg/ml cis-platin, 0.1–10 mg/ml etoposide, or 5–500 ng/ml doxorubicin). Cell survival after 24 h was deter-
mined by flow cytometric analysis of PI-stained cells and is shown as a percentage of survival in culture medium without treatment. Lymphocytes cul-
tured with control Neuro-2A cells were indistinguishable from lymphocytes cultured in medium alone. Data points represent the mean 6 SD for greater
than three mice of each genotype. 
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cytes. Our results show that in resting lymphocytes, these
anticancer treatments trigger apoptosis signaling pathways
that can be regulated by Bcl-2 and p53. Significantly, nei-
ther of these proteins influenced Fas death signaling (Fig. 1).
These results and those of others (27, 28) directly contra-
dict a recent study suggesting that Bcl-2 confers drug resis-
tance via inhibition of nuclear factor of activated T lym-
phocytes (NFAT)-induced FasL expression (3). Increased
Fas expression in response to anticancer drugs was reported
to be dependent on p53, but the issue of whether induc-
tion of the Fas gene is essential for p53-induced apoptosis
was not addressed (29). Our data from lymphocytes, together
Figure 2. Lymphocytes lacking Fas or FADD/MORT1 function are normally sensitive to killing by gamma irradiation or cytotoxic drugs. Thy-
mocytes (A), resting T (B) and B cells (C), and activated T (D) and B cells (E) from wild-type (s), bcl-2 transgenic (h), FADD-DN transgenic (m), lpr
(j), or p532/2 (d) mice were subjected to gamma radiation or cytotoxic drugs as in Fig. 1. Cell survival was determined after 24 and 48 h by flow cy-
tometric analysis of PI-stained cells and is shown as a percentage of that in culture medium without treatment. Data points represent the mean 6 SD for
greater than three mice of each genotype. 
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with the finding that FADD/MORT1- (30) or caspase-8–
deficient (31) mouse embryo fibroblasts are resistant to kill-
ing by FasL but normally sensitive to drug-induced apop-
tosis, indicates that Fas is not a common mediator of cell
killing by cytotoxic agents. By contrast, certain mouse cell
types lacking Apaf-1 or caspase-9 are resistant to both p53-
induced apoptosis (32) and killing by ionizing radiation or
cytotoxic drugs (33–36). These observations support a model
in which ionizing radiation and cytotoxic drugs trigger apop-
tosis via p53 and Apaf-1–mediated activation of caspase-9,
whereas apoptosis signaling by death receptors such as Fas is
dispensable (Fig. 4). Low levels of apoptosis in 
 
p53
 
2
 
/
 
2
 
 rest-
ing lymphocytes after drug treatment may be due to
p53-related proteins such as p73. Recent studies implicate
phosphorylation of p73 by the tyrosine kinase c-Abl as a
crucial event in apoptosis induced by gamma radiation or
cis-platin (37–39). However, the mechanism by which p73
triggers apoptosis remains to be established. Failure of en-
forced Bcl-2 expression or loss of p53 to perturb the death
of activated B and T cells treated with ionizing radiation or
cytotoxic drugs (Figs. 1 and 2) may reflect reproductive/
necrotic cell death (40). Thus, even though apoptosis sig-
naling is disabled in these cells, their capacity for continued
cell growth is limited by irreparable DNA damage.
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